Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.

摘要: Background: Small bowel adenocarcinoma is a rare cancer that has generally been considered resistant to chemotherapy, although little published on the role of chemotherapy. A retrospective analysis was conducted patients with advanced small explore chemotherapy use, and gain knowledge for ongoing management future clinical trials. Patients Methods: All treated at Princess Margaret Hospital (PMH) between 1986 2004 were identified through registry. The medical records reviewed patient characteristics, treatment outcome data. Survival statistics estimated using Kaplan Meier survival curves Cox proportional regression model. Results: Data 113 reviewed. Forty-four received palliative an overall response rate (ORR) 36% during first or second line regimen (9% complete responses 27% partial responses). Newer regimens including gemcitabine irinotecan combinations appeared have higher ORR, than older fluorouracil-based regimens. Some responded more one Palliative predicted (OS) in multivariate (HR 0.47, P = 0.035). Conclusion: Chemotherapy appears activity bowel. Prospective trials evaluating benefit are required confirm this newer systemic therapies, until such time reviews as will continue guide decisions.